Clinical trial
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in…
NCT00496366 · Rutgers, The State University of New Jersey, Other · Terminated
Key facts
| NCT number | NCT00496366 |
|---|---|
| Title | Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer |
| Official title | Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in Patients With HER2/Neu-Overexpressing Advanced or Metastatic Breast Cancer |
| Lead sponsor | Rutgers, The State University of New Jersey, Other |
| Collaborators | National Cancer Institute (NCI) NIH Rutgers Cancer Institute of New Jersey |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, HER2/Neu-positive Breast Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, Lapatinib |
| Enrollment | 11 |
| Start date | Jul 23, 2007 |
| Primary completion | Dec 31, 2009 |
| Completion | Mar 20, 2017 |
| First posted | Jul 4, 2007 |
| Last update posted | Mar 21, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: